



Algeta schedules First Quarter 2010 Presentation

Oslo, Norway, 3 May 2010 - Algeta ASA (OSE: ALGETA), the focused oncology company, will announce its first quarter 2010 results on Friday, 7 May 2010. A presentation to investors, analysts and the press will take place in Oslo at 09:45 CET. Algeta's President and CEO Andrew Kay and CFO Øystein Soug will present.

The presentation will also be webcast live and can be accessed from www.algeta.com/webcast where questions can be submitted live during the presentation.

The presentation will take place at 09:45 CET at:

Hotel Continental
Stortingsgaten 24/26
0117 Oslo
Norway.

The results report and the presentation will be made available on www.algeta.com in the Investors section from 08:00 CET.

###

For further information, please contact

Andrew Kay, CEO
Øystein Soug, CFO

+47 23 00 67 42 / +47 484 01 360 (mob)
+47 23 00 79 84 / +47 906 56 525 (mob)
post@algeta.com

Dr Mark Swallow / David Dible / Helena Galilee
Citigate Dewe Rogerson

+44 (0) 207 638 9571
mark.swallow@citigatedr.co.uk

About Algeta

Algeta is a focused oncology company developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform.

Algeta's lead product Alpharadin (based on radium-223) is a first-in-class, highly targeted alpha-pharmaceutical under clinical evaluation to improve survival in patients with bone metastases from advanced cancer. Its localized action helps preserve the surrounding healthy tissue thereby limiting side-effects.

The development of bone metastases represents a serious development for cancer patients as they are associated with a dramatic decline in patient health and quality of life, ultimately leading to death. Bone metastases represent a major unmet medical need, occurring in up to 90% of certain late-stage cancers, e.g. prostate, breast and lung.

Alpharadin is partnered with Bayer Schering Pharma AG, a major pharmaceutical company, and is in a global phase III clinical trial (ALSYMPCA) to treat bone metastases resulting from castration-resistant (hormone-refractory) prostate cancer. Alpharadin is also under investigation in phase II clinical trials as a potential new treatment for bone metastases in endocrine resistant breast cancer patients.

Algeta also aims to develop a future pipeline of tumor-targeting alpha-pharmaceutical candidates based on the alpha particle emitter thorium-227, through selective in-licensing and/or acquiring innovative technologies and tumor-targeting molecules.

The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).

Alpharadin and Algeta are trademarks of Algeta ASA.

Forward-looking Statement

This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. These factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products.

###